“We are delighted to present these detailed CME-certified satellite symposia to the healthcare community at the largest gathering of oncologists in the world,” Phil Talamo, president of PER®, said. “These programs encompass both a wide range of topics and expansive international faculty, which will help inform the attendees on emerging data and novel strategies for treatment and management of many different types cancer.”

The following symposia will take place during the annual meeting:

Friday, June 1

• PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your Patients, begins at 7 p.m. in the International Ballroom South (second level). The symposia will discuss the use of PARP inhibitors to treat patients with breast cancer. The program will be chaired by Mark E. Robson, M.D., chief, breast medicine service; attending physician, breast medicine and clinical genetics services; and professor of medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center. For more information and to register, visit http://www.gotoper.com/go/Chicago18PARP
• Medical Crossfire®: The Advent of CAR-T Cell Therapy for Lymphoid Malignancies and Beyond will be held at 7 p.m. in salons A-1 and A-2 (lower level). The program will delve into the recent approval of chimeric antigen receptor T cells for treating chemorefractory hematologic malignancies. The symposia will be chaired by Andre H. Goy, M.D., M.S., chairman and executive director and lymphoma division chief, John Theurer Cancer Center; chief science officer, Regional Cancer Care Associates; Lydia Pfund Chair for Lymphoma, Seton Hall-Hackensack Meridian School of Medicine; and professor of medicine, Georgetown University. For more information and to register, visit http://www.gotoper.com/go/Chicago18CART.
• Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary Cancers will take place at 7 p.m. in the Williford Room (third level). The program will expand on the unmet clinical needs for managing genitourinary cancers, especially for patients with advanced forms of diseases. The program will be chaired by Charles G. Drake, M.D., Ph.D., professor of oncology and immunology; director, genitourinary cancer program; and co-director, immunotherapy program, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center. For more information and to register, visit http://www.gotoper.com/go/Chicago18GU.

Saturday, June 2

• New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of Immunotherapy will take place at 7 p.m. in the International Ballroom South (second level). The program will discuss the issue that patients with unresectable cutaneous squamous cell carcinoma respond to any currently available treatment only about 30% of the time. The program will be chaired by Jason Luke, M.D., assistant professor of medicine, the University of Chicago Medicine. For more information and to register, visit http://www.gotoper.com/go/Chicago18SCC.
• Matching Treatment to Patient in an Ever-Changing Era for the Management of Advanced Renal Cell Carcinoma: An Expert Tumor Board Discussion will be held at 7 p.m. in salons A-1 and A-2 (lower level). Attendees will learn about recent and pending approvals of new agents and combinations, and gain real-world experience with newest agents and emerging trial data. The event will be chaired by Toni K. Choueiri, M.D., director, Lank Center for Genitourinary Oncology and Kidney Cancer Center; senior physician, Dana-Farber Cancer Institute; and Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School. For more information and to register, visit http://www.gotoper.com/go/Chicago18mRCC.

Sunday, June 3

• Medical Crossfire®: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid Foundation will begin at 7 p.m. in the International Ballroom North (second level). Attendees will gain insight on key learning points pertaining to the use of PARP inhibition in ovarian cancer. This live, fast-paced discussion will be chaired by Robert L. Coleman, M.D., professor and executive director, cancer network research, and Ann Rife Cox Chair in Gynecology, department of gynecologic oncology and reproductive medicine, the University of Texas MD Anderson Cancer Center. For more information and to register, visit http://www.gotoper.com/go/Chicago18MP.
• Navigating New Sequencing Challenges for the Treatment of Hepatocellular Carcinoma will begin at 7 p.m. in the International Ballroom South (second level). The program will explore the evolving natural history of hepatocellular carcinoma and key clinical trial data that are changing the treatments for patients with this disease. The program will be chaired by Alan P. Venook, M.D., Madden Family Distinguished Professor in medical oncology and translational research and Shorenstein associate director for program development, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco. For more information and to register, visit http://www.gotoper.com/go/Chicago18HCC.
• Transforming Treatment Paradigms in Renal Cell Carcinoma: Understanding the Role of Risk Stratification and Emerging Data in the Adjuvant Setting will begin at 7 p.m. in Salon A-5 (lower level). Attendees will learn about best practices for risk assessment and patient selection for adjuvant renal cell carcinoma therapy and receive an up-to-date review of risk and assessment in the early-stage disease setting. The program will be chaired by Robert A. Figlin, M.D., Steven Spielberg Family Chair in Hematology Oncology; professor of medicine and biomedical sciences; director, division of hematology/oncology; and deputy director, integrated oncology service line, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center. For more information and to register, visit http://www.gotoper.com/go/Chicago18aRCC.

About PER®

Since 1995, Physicians’ Education Resource, LLC® (PER®) has been the leading provider of live and online continuing medical education activities on oncology and hematology by providing high-quality, evidence-based activities featuring leading experts who focus on the application of practice-changing advances. In 2018, PER® will develop and implement 20 historic annual legacy conferences in the United States and Europe, along with many world-renowned online learning formats such as Medical Crossfire®. PER® is accredited by both the Accreditation Council for Continuing Medical Education and the California Board of Registered Nursing. PER® is part of the Cranbury, New Jersey-based MJH Associates Inc. family of businesses. Learn more at gotoper.com and mjhassoc.com.